Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

The Food and Drug Administration (FDA) and Bristol-Myers Squibb are notifying healthcare professionals of revisions to the microbiology/Antiviral Activity and indications and usage/Description of Clinical Studies/Special Populations sections of the prescribing information for entecavir (Baraclude), a nucleoside analog used in the treatment of chronic hepatitis B virus (HBV).

FDA Notifications